What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in all serious systemic adverse events (low certainty).

• Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration 2014 · Cochrane Headline outcomes only
  RR 1.08 [0.9, 1.31]
  9 studies · 3665 participants
  Low